Serina Therapeutics (SER) Receivables - Net (2017 - 2024)

Serina Therapeutics has disclosed Receivables - Net across 8 years of filings, most recently posting $65000.0 for Q1 2024.

• In Q1 2024, Receivables - Net rose 983.33% year-over-year to $65000.0; the TTM figure through Mar 2024 stood at $65000.0 (up 983.33% YoY), while the FY2023 annual figure was $57000.0, up 1325.0% from the prior year.
• Receivables - Net came in at $65000.0 for Q1 2024 at Serina Therapeutics, up from $57000.0 in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $366000.0 in Q1 2020 to a low of $1000.0 in Q3 2022.
• Average Receivables - Net over 5 years is $93375.0, with a median of $36500.0 recorded in 2021.
• Year-over-year, Receivables - Net plunged 95.83% in 2022 and surged 6600.0% in 2023.
• Over 5 years, Receivables - Net stood at $326000.0 in 2020, then slumped by 92.33% to $25000.0 in 2021, then sank by 84.0% to $4000.0 in 2022, then jumped by 1325.0% to $57000.0 in 2023, then rose by 14.04% to $65000.0 in 2024.
• Per Business Quant data, the three most recent Receivables - Net figures were $65000.0 in Q1 2024, $57000.0 in Q4 2023, and $67000.0 in Q3 2023.